一、募集资金基本情况 申港证券股份有限公司 关于贵州三力制药股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 申港证券股份有限公司（以下简称"申港证券"或"保荐机构"）作为贵州 三力制药股份有限公司（以下简称"贵州三力"或"公司"）首次公开发行股票并上 市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所股票上市 规则》和《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律 法规的要求，对贵州三力 2023 年度募集资金存放与使用情况进行了专项核查， 具体核查情况如下： （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准贵州三力制药股份有限公司首次公开 发行股票的批复》（证监许可[2020]561号）核准，公司向社会公开发行人民币 普通股股票（A股）4,074万股，每股发行价格为7.35元，共计募集货币资金人民 币299,439,000.00元，扣除与发行有关的不含税费用人民币62,598,000.00元，公 司实际募集资金净额为人民币236,841,000.00元。该募集资 ...

贵州三力制药股份有限公司 一、独立董事的基本情况 公司董事会由7名董事组成，其中独立董事3人，占董事会成员人 数的三分之一以上，符合相关法律法规及公司制度的规定。 本人陈世贵：男，中国国籍，1963年11月生，无永久境外居留权， 注册会计师、注册资产评估师、注册税务师、注册房地产估价师、注 册土地估价师。1996年7月取得北京航空航天大学管理工程专业工学 学士学位。历任顺德智信会计师事务所审计部部长、贵阳新华会计师 事务所所长助理、云南亚太会计师事务所贵州分所副总经理、亚太中 汇会计师事务所有限公司副总经理。现任中审亚太会计师事务所有限 公司贵州分所副总经理、上海神奇制药投资管理股份有限公司独立董 事。2022年12月12日至今，任公司第三届董事会独立董事。 作为公司独立董事，本人及直系亲属、主要社会关系没有在公司 及其附属企业任职，也没有在直接或间接持有公司5%或5%以上已发行 股份的股东单位任职；没有为公司及其附属企业提供财务、法律、管 理咨询、技术咨询等有偿服务，也没有从公司及其主要股东单位或有 利害关系的机构取得未予披露的其他利益，不存在影响独立性的情况。 二、独立董事年度履职概况 (一)出席董事会及 ...

证券代码：603439 证券简称：贵州三力 公告编号：2024-010 贵州三力制药股份有限公司 关于续聘会计师事务所公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：北京大华国际会计师事务所（特殊普通 合伙）（以下简称"北京大华国际"） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 名称：北京大华国际会计师事务所（特殊普通合伙） 成立日期：2008 年 12 月 8 日 组织形式：特殊普通合伙 注册地址：北京市西城区阜成门外大街 3 号 5 层 519A 首席合伙人：杨雄 职业风险基金上年度年末数：105.35 万元；已购买的职业保险累计赔偿限 额 2 亿元。职业风险基金计提和职业保险购买符合相关规定；近三年无在执业 行为相关民事诉讼中承担民事责任的情况。 3. 诚信记录。 北京大华国际近三年因执业行为受到刑事处罚 0 次、行政处罚 0 次、监督 管理措施 0 次、自律监管措施 0 次和纪律处分 0 次。期间有 13 名从业人员 近三年因执业行为受到监督管理措施 ...

关于贵州三力制药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：贵州三力制药股份有限公司 审计单位：北京大华国际会计师事务所（特殊普通合伙） 联系电话：0851-84607958 贵州三力制药股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2023 年 12 月 31 日） 目 页 次 第 1 页 控股股东及其他关联方资金占用情况的专项 1-2 Í 说明 1 Í 贵州三力制药股份有限公司 2023 年度非经营 l 性资金占用及其他关联资金往来情况汇总表 x 大学国际会計师事务所 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 北京大华核字[2024]00000138 号 贵州三力制药股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了贵州三 力制药股份有限公司（以下简称贵州三力）2023 年度财务报表,包 括 2023 年 12 月 31 日的合并及母公司资产负债表,2023 年度的合并 及母公司利润表、合并及母公司现金流量表和合并及母公司股东权益 变动表以 ...

贵州三力制药股份有限公司 内部控制审计报告 北京大华内字[2024]00000023 号 北京大华国际会计师事务所 (特殊普通合伙 ) Beijing Dahua International Certified Public Accountants (Limited Liability Partnership) 贵州三力制药股份有限公司 北京大华国际会计师事务所（特殊普通合伙） 北京市西城区阜成门外大街 31 号五层 519A [100071] 电话：86 (10) 6827 8880 传真：86 (10) 6823 8100 内部控制审计报告 内部控制审计报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 北京大华内字[2024]00000023 号 贵州三力制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了贵州三力制药股份有限公司（以下简称贵州三力） 2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控 ...

贵州三力制药股份有限公司 第五条 审计委员会设召集人一名，须为会计专业人士且为独立董事，负责主持委员会工 作。召集人在委员会内选举产生，并报请董事会批准。 第六条 审计委员会任期与董事会一致，委员任期届满后，连选可以连任。 贵州三力制药股份有限公司 董事会审计委员会工作细则 （2024 年修订版） 第一章 总 则 第一条 为强化贵州三力制药股份有限公司（以下简称"公司"）董事会决策功能，做到事 前审计、专业审计，确保对公司财务收支和各项经营活动的有效监督，完善公司法人治理结 构，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事管理办 法》《上市公司治理准则》《上海证券交易所上市公司自律监管指引第1号——规范运作》等 法律法规、规范性文件以及《贵州三力制药股份有限公司章程》（以下简称"《公司章 程》"）等有关规定，公司特设立董事会审计委员会（以下简称"审计委员会"），并制定董 事会审计委员会工作细则（以下简称"本工作细则"）。 第二条 审计委员会是董事会下设的专门工作机构，主要负责审核公司财务信息及其披露、 监督及评估内外部审计工作和内部控制。 第二章 审计委员会的产生与组成 第三条 审计 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 422,024,144.62, representing a year-on-year increase of 20.93%[5] - The net profit attributable to shareholders for the same period was CNY 56,048,131.61, with a growth of 2.03% compared to the previous year[5] - The basic earnings per share (EPS) was CNY 0.14, reflecting an increase of 7.69% year-on-year[5] - The net profit for Q1 2024 was ¥56,860,529.64, representing a 6.9% increase from ¥53,396,249.70 in Q1 2023[17] - In Q1 2024, the company reported a net profit of 56,860,529.64 RMB, an increase from 53,396,249.70 RMB in Q1 2023, representing a growth of approximately 4.3%[18] - The overall comprehensive income attributable to the parent company was 56,048,131.61 RMB in Q1 2024, up from 54,932,724.23 RMB in Q1 2023, reflecting a growth of approximately 2%[18] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 2,946,600,361.23, a slight increase of 0.90% from the end of the previous year[6] - The total assets of the company as of March 31, 2024, were ¥2,946,600,361.23, slightly up from ¥2,920,451,107.53 at the end of 2023[14] - The total liabilities decreased to ¥1,155,505,033.80 from ¥1,211,097,697.17 at the end of 2023, indicating a reduction in financial obligations[14] - The company's equity attributable to shareholders increased to ¥1,539,903,554.84 from ¥1,470,311,172.51 at the end of 2023, indicating growth in shareholder value[14] Cash Flow - The net cash flow from operating activities was CNY 6,107,280.58, showing improvement as the previous year's figure was negative[5][7] - Cash flow from operating activities generated a net cash inflow of 6,107,280.58 RMB in Q1 2024, a significant improvement from a net outflow of -1,351,706.77 RMB in Q1 2023[21] - The company received 462,161,879.85 RMB in cash from sales of goods and services in Q1 2024, compared to 330,487,785.44 RMB in Q1 2023, marking a growth of about 39.8%[21] - Cash outflows for operating activities totaled 458,773,664.15 RMB in Q1 2024, compared to 339,248,689.86 RMB in Q1 2023, indicating an increase of approximately 35.3%[21] - The company reported a net cash outflow from investing activities of -10,385,541.40 RMB in Q1 2024, an improvement from -112,077,228.06 RMB in Q1 2023[21] - Cash inflow from financing activities in Q1 2024 was 24,200,000.00 RMB, with a net cash inflow of 16,865,454.05 RMB after financing outflows, compared to a net outflow of -2,223,791.67 RMB in Q1 2023[22] Shareholder Information - The company had a total of 22,032 common shareholders at the end of the reporting period[9] - The largest shareholder, Zhang Hai, holds 46.03% of the shares, with 94,145,600 shares pledged[10] Costs and Expenses - The total operating costs for Q1 2024 were ¥354,161,051.46, up 22.4% from ¥289,432,187.31 in Q1 2023[17] - Research and development expenses for Q1 2024 were ¥8,891,832.83, an increase of 77.5% compared to ¥5,014,006.28 in Q1 2023[17] Inventory and Receivables - The company reported a significant increase in accounts receivable, totaling ¥551,144,801.91 as of March 31, 2024, compared to ¥546,266,433.92 at the end of 2023[12] - The inventory level rose to ¥231,895,435.21 as of March 31, 2024, compared to ¥175,724,948.92 at the end of 2023, reflecting increased stock levels[12] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]

Financial Performance - The audited net profit attributable to shareholders for 2023 is CNY 292,702,869.34, with the parent company's distributable profit at CNY 694,947,388.84[4] - In 2023, the company's operating revenue reached RMB 1.63 billion, a year-on-year increase of 36.10%[21] - The net profit attributable to shareholders was RMB 292.70 million, up 45.42% compared to the previous year[21] - The net profit after deducting non-recurring gains and losses was RMB 245.65 million, reflecting a 26.21% increase year-on-year[21] - Total assets increased by 60.76% year-on-year, reaching RMB 2.92 billion, primarily due to the mergers with Hanfang Pharmaceutical and Wudi Pharmaceutical[21] - The weighted average return on equity rose to 21.45%, an increase of 3.71 percentage points from the previous year[22] - The company achieved a net cash flow from operating activities of RMB 276.70 million, a decrease of 5.65% compared to the previous year[21] - The company’s equity attributable to shareholders increased by 18.66% year-on-year, amounting to RMB 1.47 billion[21] - The company reported a significant increase in manufacturing costs for the pharmaceutical sector, rising by 207.64% to CNY 51,076,010.22[71] - The company reported a total of 2,282 employees, with 1,316 in the parent company and 966 in major subsidiaries[157] Profit Distribution - The proposed profit distribution plan for 2023 is a cash dividend of CNY 2.00 per 10 shares (tax included), with no bonus shares or capital reserve conversion[4] - The total cash dividend amount, including the repurchase of shares, is RMB 111,645,063.20, accounting for 38.14% of the net profit attributable to ordinary shareholders in the consolidated financial statements[164] - The total cash dividend to be distributed is RMB 81,650,263.20, which represents a cash dividend ratio of 27.90% of the net profit attributable to ordinary shareholders in the consolidated financial statements[161] Compliance and Governance - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting potential risks[5] - The company confirms that there are no violations in decision-making procedures for external guarantees[7] - The board of directors and management guarantee the authenticity and completeness of the annual report, with no significant omissions[10] - The company operates under the regulatory guidance of the China Securities Regulatory Commission and the Shanghai Stock Exchange[13] - The company has held four shareholder meetings in 2023, ensuring compliance with legal and regulatory requirements[141] Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings, particularly in the OTC and traditional medicine sectors[13] - The company has diversified its product structure and expanded its marketing team to enhance OTC channel development[29] - The company expanded its sales channels, adding over 700 hospital channels and 600 small chain pharmacies, significantly boosting product sales stability[36] - The company is actively collaborating with hospitals and universities for clinical research, enhancing the evidence base for its core products and addressing the efficacy of traditional Chinese medicine[38] - The company is committed to exploring mergers and acquisitions in the health sector to drive significant growth and expand its pharmaceutical footprint[132] Research and Development - The company is committed to advancing digital production and research transformation to enhance its core competitiveness in the traditional Chinese medicine sector[39] - The company has established long-term strategic partnerships with multiple research institutions and universities to improve product quality and safety, focusing on new product development and existing product evaluations[55] - The company is conducting a multi-center clinical trial for its core product, the throat spray, expected to be completed within three years[96] - The company is developing several new traditional Chinese medicine products, including Xie Bai San and Qiang Huo Sheng Shi Tang, which are currently in the pharmaceutical research stage[100] - The company has ongoing research on the efficacy and safety of the "Qi Jiao Sheng Bai Capsule," which is aimed at treating symptoms related to blood deficiency, with plans for market launch after further studies[105] Environmental Responsibility - The company invested CNY 3.71 million in environmental protection during the reporting period[171] - The wastewater treatment facility has a capacity of 100 tons per day, achieving over 98% removal rates for COD and ammonia nitrogen[174] - The company has a dedicated hazardous waste storage facility, managed by specialized personnel, ensuring compliance with pollution control standards[176] - The company has established emergency response plans for environmental incidents, filed with local environmental protection agencies[178] - The company has a comprehensive environmental self-monitoring plan in place, ensuring regular assessments of emissions and wastewater quality[180] Human Resources and Management - The company has a structured management team with a mix of experienced professionals, ensuring continuity in leadership and strategic direction[143] - The total remuneration for the reporting period for directors and senior management amounted to 437.83 million yuan[143] - The company has implemented a performance-based compensation system linked to job value and contribution, enhancing its incentive mechanisms[158] - The company conducted 123 training sessions during the reporting period to enhance employee skills and strengthen corporate culture[160] - The company has a stock incentive plan in place, with 2,540,000 restricted shares granted to key management personnel, of which 1,016,000 shares have been unlocked[166]

贵州三力制药股份有限公司 独立董事年度述职报告 根据中国证监会《上海证券交易所股票上市规则》（2023年8月 修订）、《上市公司治理准则》、《上市公司独立董事管理办法》和 《贵州三力制药股份有限公司公司章程》（以下简称"《公司章程》"） 等有关规定，作为贵州三力制药股份有限公司（以下简称"公司"） 独立董事，本人勤勉尽责地履行独立董事职责，积极出席相关会议， 认真审议董事会各项议案，切实维护了公司整体利益和全体股东尤其 是中小股东的利益。 现就2023年度履职情况报告如下： 一、独立董事的基本情况 公司董事会由7名董事组成，其中独立董事3人，占董事会成员人 数的三分之一以上，符合相关法律法规及公司制度的规定。 本人王强：男，中国国籍，1970年1月生，无永久境外居留权， 工商管理硕士，会计师、审计师、中国注册会计师、中国注册资产评 估师。1993年7月至1996年9月任贵阳市审计局工交处审计员；1996 年10月至1999年10月任贵阳审计师事务所评估主任；1999年11月至今, 任贵阳安达会计师事务所副所长；2006年4月至今任贵州君安房地产 土地资产评估有限公司执行董事，贵州省注册会计师协会理事(曾任 中 ...

证券代码：603439 证券简称：贵州三力 公告编号：2024-018 贵州三力制药股份有限公司 关于首次公开发行股票募投项目结项并将节余 募集资金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为进一步加强募集资金的管理和运用，提高募集资金使用效率，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司监管指引第2号—— 上市公司募集资金管理和使用的监管要求》和上海证券交易所发布的《上海证券 交易所上市公司自律监管指引第1号——规范运作》等有关法律法规和规范性文 件，结合公司实际情况，公司制订了《贵州三力制药股份有限公司募集资金管理 制度》。根据上述管理制度的规定，公司对募集资金实行专户存储。 公司已与保荐机构申港证券股份有限公司于2020年4月22日分别同贵阳银行 股份有限公司平坝支行、招商银行股份有限公司贵阳分行、中国工商银行股份有 限公司贵阳南明支行签订了《募集资金专户存储三方监管协议》。上述监管协议 明确了各方的权利和义务，协议主要条款与上海证券交易所《募集资金专户存 ...